Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
OMIM | RCV000018008 | SCV000038287 | risk factor | Hemolytic uremic syndrome, atypical, susceptibility to, 1 | 2003-04-01 | no assertion criteria provided | literature only | |
Sydney Genome Diagnostics, |
RCV001328244 | SCV001449222 | pathogenic | Atypical hemolytic-uremic syndrome | 2017-10-25 | no assertion criteria provided | clinical testing | This individual is heterozygous for the c.3643C>G variant in the CFH gene. The c.3643C>G variant has not been reported in any population databases (i.e. gnomAD, ExAC or ESP). This variant has been previously described in the literature and the FH aHUS Mutation Database (http://www.fh-hus.org/fullList.php?protein=FH). In particular, this variant (first reported as R1197G, then R1215G) has been reported in the heterozygous state in multiple affected individuals in a large pedigree, including two individuals with first presentation at 5 months (Edelsten and Tuck 1978 Arch Dis Child 53:255-256; Warwicker et al 1998 Kidney International 53: 836-844; Sansbury et al 2014 Med Genet 51:756-764). The pedigree supported an autosomal dominant mode of inheritance, with incomplete penetrance. In vitro analysis of the p.Arg1215Gly mutant protein showed significant impact on protein function, indicative of loss-of-function (Jozsi et al 2006 J Am Soc Nephrol 17:170-177; Ferreira et al 2009 J Immunol 192:7009-7018). This variant is considered to be pathogenic according to the ACMG guidelines. |